Astrazeneca PLC (AZN) Sees Strong Trading Volume
Astrazeneca PLC (NYSE:AZN) saw unusually-high trading volume on Tuesday . Approximately 8,834,226 shares were traded during mid-day trading, an increase of 22% from the previous session’s volume of 7,245,326 shares.The stock last traded at $30.23 and had previously closed at $29.97.
AZN has been the topic of a number of analyst reports. Goldman Sachs Group Inc. downgraded Astrazeneca PLC from a “neutral” rating to a “sell” rating in a research note on Monday, April 11th. JPMorgan Chase & Co. restated a “neutral” rating on shares of Astrazeneca PLC in a research note on Thursday, March 24th. Bank of America Corp. restated a “buy” rating on shares of Astrazeneca PLC in a research note on Thursday, March 24th. Citigroup Inc. restated a “buy” rating on shares of Astrazeneca PLC in a research note on Friday, April 1st. Finally, Beaufort Securities reiterated a “hold” rating on shares of Astrazeneca PLC in a research report on Thursday, March 31st. Two research analysts have rated the stock with a sell rating, ten have assigned a hold rating, eleven have issued a buy rating and two have given a strong buy rating to the company. Astrazeneca PLC currently has a consensus rating of “Buy” and an average price target of $628.54.
The firm has a 50 day moving average of $29.21 and a 200 day moving average of $29.70. The company has a market capitalization of $76.68 billion and a P/E ratio of 26.36.
Astrazeneca PLC (NYSE:AZN) last released its quarterly earnings data on Friday, April 29th. The company reported $0.51 earnings per share for the quarter, missing the consensus estimate of $0.60 by $0.09. During the same period in the previous year, the company posted $1.08 earnings per share. The firm earned $6.12 billion during the quarter, compared to analyst estimates of $5.96 billion. The firm’s quarterly revenue was up 1.0% on a year-over-year basis. On average, analysts expect that Astrazeneca PLC will post $2.36 EPS for the current fiscal year.
Other large investors recently added to or reduced their stakes in the company. Wells Fargo & Company MN raised its stake in Astrazeneca PLC by 7.6% in the fourth quarter. Wells Fargo & Company MN now owns 2,009,893 shares of the company’s stock valued at $68,236,000 after buying an additional 141,767 shares in the last quarter. Dimensional Fund Advisors LP boosted its stake in shares of Astrazeneca PLC by 3.6% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,884,300 shares of the company’s stock valued at $63,972,000 after buying an additional 65,433 shares during the period. Morgan Stanley boosted its stake in shares of Astrazeneca PLC by 16.3% in the fourth quarter. Morgan Stanley now owns 1,572,388 shares of the company’s stock valued at $53,382,000 after buying an additional 220,787 shares during the period. Tamarack Advisers LP acquired a new stake in shares of Astrazeneca PLC during the fourth quarter valued at approximately $13,580,000. Finally, First Trust Advisors LP boosted its stake in shares of Astrazeneca PLC by 45.6% in the fourth quarter. First Trust Advisors LP now owns 228,507 shares of the company’s stock valued at $7,758,000 after buying an additional 71,598 shares during the period.
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.